[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100443736":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":51,"collaborators":11,"id":53,"slug":11,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":11,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":11,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Hospital for Special Surgery, New York","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1: Topical Steroid","EXPERIMENTAL",null,[13],"Drug: Depo-Medrol 40Mg\u002FMl Suspension for Injection",{"label":15,"type":16,"description":11,"interventionNames":17},"Group 2: Topical Normal Saline","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Depo-Medrol 40Mg\u002FMl Suspension for Injection","40mg Depo-Medrol mixed with hemostatic matrix",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Placebo","1 mL of sterile normal saline mixed with hemostatic matrix",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Catherine Himo Gang, MPH","CONTACT","(917) 623-5416","gangh@hss.edu",[36],{"facility":37,"status":38,"city":39,"state":39,"zip":40,"country":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Hospital for Special Surgery","RECRUITING","New York","10021","United States",{"type":43,"coordinates":44},"Point",[45,46],-74.00597,40.71427,{"lat":46,"lon":45},[49],{"name":50,"role":32,"phone":11,"phoneExt":11,"email":11},"Matthew Cunningham, MD, PhD",{"type":52,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100443736",false,"NCT05058287","Lumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression","Topical Epidural Steroid Usage in Patients Undergoing Posterior Lumbar Decompression: A Randomized Control Trial","Inclusion Criteria:\n\n* Patients scheduled to undergo 1 to 2 level laminectomy\n* Between the ages of 18-85\n\nExclusion Criteria:\n\n* Minimally invasive surgery\n* Prior daily opioid usage within 6 months.\n* Use of concomitant procedures such as spinal fusion, revision procedure at the same level.\n* History of a chronic pain syndrome, uncontrolled diabetes defined as A1C \\> 6.5, immunocompromised condition such as active cancer treatment, history of transplant, benign prostatic hyperplasia or history of urinary retention, and other conditions which require chronic steroid therapy or immunosuppressants.\n* Non-English speakers\n* Patients allergic to Depo-Medrol and\u002For glucocorticoids, or other steroids","ALL","18 Years","85 Years",{"count":63,"type":64},150,"ESTIMATED","INTERVENTIONAL",[67],"PHASE3","This study seeks to evaluate the impact of intra-operative topical epidural steroid usage in patients undergoing 1-2 level lumbar laminectomy. The study will examine post-operative opioid usage, length of stay, return to work, and patient reported outcomes following these procedures.",[70,71,72,73],"Opioid Use","Lumbar Spinal Stenosis","Pain, Postoperative","Pain, Back","2026-04-23",{"date":76,"type":77},"2026-04-28","ACTUAL",{"date":79,"type":77},"2021-11-05",{"date":81,"type":64},"2026-12-31",{"name":5,"class":6},1]